<p>Means (SD), median (25<sup>th</sup> –75<sup>th</sup> percentile), or proportions.</p><p>PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor.</p>a<p>P-values are for comparison of HIV− to HIV+ participants.</p>b<p>P-values are for comparison of HIV+/HAART+ to HIV+/HAART− participants.</p>c<p>Illicit drug use was defined as any use of marijuana, nitrite inhalants, crack or cocaine, stimulants, or other illicit drugs since the last MACS visit.</p><p>*P < 0.05, compared to HIV−.</p>†<p>P < 0.05, HIV+/HAART+ compared to HIV+/HAART−.</p><p>Comparisons of data represented with means were performed using t-tests for 2-group comparisons and linear regression with robus...
<p><b>NOTE.</b> Data are expressed as mean ± SD or number (percent). <sup>a</sup>Independent sample ...
<p><b>Copyright information:</b></p><p>Taken from "Injection drug use and patterns of highly active ...
<p>The table shows characteristics of partners of HIV-uninfected participants who were enrolled in B...
<p><i>Note.</i> Values represent Mean (standard deviation) unless otherwise indicated; WTAR = Wechsl...
<p>Note: BP = bacterial pneumonia; CI = confidence interval; HAART = highly active antiretroviral th...
<p>All patients were male, non smokers.</p><p>*Significance determined using a Kruskal-Wallis equali...
<p>Age, T cell counts, viral loads, years diagnosed and years on HAART are expressed as mean values ...
<p>The table shows characteristics of HIV-uninfected participants who were enrolled in Baltimore, MD...
<p>SAT, self-administered therapy; DAART, directly administered therapy; PI, protease inhibitor; NRT...
<p>Data are presented as median (IQR) or percentage. Differences between groups were compared by Man...
<p>(N = 7473).</p>a<p>P-value reported using the Kruskal-Wallis test; <sup>b</sup> P-value not signi...
<p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use...
<p>All parameters expressed as median and (interquartile range) unless indicated. HALS = HIV-1/HAART...
<p>*Dose groups significantly different p<0.05</p><p><sup>a</sup> n = 59, one subject had unknown HI...
<p> <b>Note:</b></p><p>Unless otherwise denoted, all groups are significantly differen...
<p><b>NOTE.</b> Data are expressed as mean ± SD or number (percent). <sup>a</sup>Independent sample ...
<p><b>Copyright information:</b></p><p>Taken from "Injection drug use and patterns of highly active ...
<p>The table shows characteristics of partners of HIV-uninfected participants who were enrolled in B...
<p><i>Note.</i> Values represent Mean (standard deviation) unless otherwise indicated; WTAR = Wechsl...
<p>Note: BP = bacterial pneumonia; CI = confidence interval; HAART = highly active antiretroviral th...
<p>All patients were male, non smokers.</p><p>*Significance determined using a Kruskal-Wallis equali...
<p>Age, T cell counts, viral loads, years diagnosed and years on HAART are expressed as mean values ...
<p>The table shows characteristics of HIV-uninfected participants who were enrolled in Baltimore, MD...
<p>SAT, self-administered therapy; DAART, directly administered therapy; PI, protease inhibitor; NRT...
<p>Data are presented as median (IQR) or percentage. Differences between groups were compared by Man...
<p>(N = 7473).</p>a<p>P-value reported using the Kruskal-Wallis test; <sup>b</sup> P-value not signi...
<p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use...
<p>All parameters expressed as median and (interquartile range) unless indicated. HALS = HIV-1/HAART...
<p>*Dose groups significantly different p<0.05</p><p><sup>a</sup> n = 59, one subject had unknown HI...
<p> <b>Note:</b></p><p>Unless otherwise denoted, all groups are significantly differen...
<p><b>NOTE.</b> Data are expressed as mean ± SD or number (percent). <sup>a</sup>Independent sample ...
<p><b>Copyright information:</b></p><p>Taken from "Injection drug use and patterns of highly active ...
<p>The table shows characteristics of partners of HIV-uninfected participants who were enrolled in B...